Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Oral BGE-102
BGE-102 · 1 trial · 1 indication
Percent change in hsCRP of the BGE-102 Dose A daily compared to Placebo
Percent change in hsCRP of the BGE-102 Dose B daily compared to Placebo
Percent change in hsCRP of the BGE-102 Dose C daily compared to Placebo
| Arm | Type | Description |
|---|---|---|
| Arm A: BGE-102 Dose A | EXPERIMENTAL | capsules dosed once daily in the morning |
| Arm B: BGE-102 Dose B | EXPERIMENTAL | capsules dosed once daily in the morning |
| Arm C: BGE-102 Dose C | EXPERIMENTAL | capsules dosed once daily in the morning |
| Arm D: Dose D | PLACEBO_COMPARATOR | capsules dosed once daily in the morning |
| Name | Type | Description |
|---|---|---|
| Oral BGE-102 | DRUG | Capsules |
| Oral Placebo Matching BGE-102 | DRUG | Capsules |
Key Inclusion Criteria: * Obese Male and Female adults with BMI 32-42 kg/m² * Elevated blood test for hsCRP consistent with chronic systemic inflammation * At least one cardiovascular risk factor or metabolic syndrome feature * Stable background therapies and willing to maintain stable diet/exercis...
BGE-102 is an investigational oral small molecule developed by BioAge Labs, Inc. for obesity and cardiovascular risk. It is also known as Oral BGE-102. The drug is currently in Phase 2 clinical development and has not been approved by the FDA.
BGE-102 is being studied for the treatment of obesity and cardiovascular risk factors. Its Phase 2 trial enrolls adults with obesity and cardiovascular risk factors. The drug is investigational and has not been approved for any indication.
BGE-102 targets NLRP3, a component of the inflammasome, and acts as an NLRP3 inhibitor. By inhibiting NLRP3, the drug is designed to modulate inflammatory signaling relevant to obesity and cardiovascular risk. It is an orally administered small molecule.
BGE-102 is developed by BioAge Labs, Inc., which trades under the ticker BIOA. BioAge Labs is the sponsor of the Phase 2 clinical program evaluating BGE-102 in obesity and cardiovascular risk.
BGE-102 is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. The Phase 2 study is active but not recruiting, and no trials of BGE-102 have been completed.
BGE-102 is being evaluated in one active Phase 2 trial, NCT07656727, titled a study of the pharmacodynamics, safety and tolerability of BGE-102 in participants with obesity and cardiovascular risk factors. The randomized, double-blind, placebo-controlled trial has an enrollment of 160 and is conducted in the United States and Puerto Rico.
Yes, Oral BGE-102 is another name for BGE-102. Both refer to the same investigational NLRP3 inhibitor small molecule developed by BioAge Labs, Inc. for obesity and cardiovascular risk. The oral designation reflects its route of administration.